Xcorporeal (OTCMKTS:XCRP) & Sight Sciences (NASDAQ:SGHT) Head to Head Analysis

Xcorporeal (OTCMKTS:XCRP) and Sight Sciences (NASDAQ:SGHT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability.

Analyst Ratings

This is a breakdown of current ratings for Xcorporeal and Sight Sciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xcorporeal	0	0	0	0	0.00
Sight Sciences	1	3	5	0	2.44

Sight Sciences has a consensus price target of $8.14, suggesting a potential upside of 43.12%. Given Sight Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe Sight Sciences is more favorable than Xcorporeal.

Institutional & Insider Ownership

55.5% of Sight Sciences shares are held by institutional investors. 30.9% of Sight Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Xcorporeal and Sight Sciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xcorporeal	N/A	N/A	N/A	N/A	N/A
Sight Sciences	$77.36 million	4.00	-$38.43 million	($0.71)	-8.01

Xcorporeal has higher earnings, but lower revenue than Sight Sciences.

Profitability

This table compares Xcorporeal and Sight Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xcorporeal	N/A	N/A	N/A
Sight Sciences	-46.83%	-52.34%	-28.49%

Summary

Sight Sciences beats Xcorporeal on 6 of the 9 factors compared between the two stocks.

About Xcorporeal

Xcorporeal, Inc. is in the process of liquidation and dissolution, pursuant to the plan adopted by board of directors of the company on February 4, 2010. The company has formed the liquidating trust, Xcorporeal, Inc. Liquidating Trust, and transferred all of its assets to the trust for the purpose of completing the liquidation and dissolution of the company. Previously, it operated as a medical device company, which was engaged in the development of an extra-corporeal platform technology to be used in devices to replace the function of various human organs. Xcorporeal, Inc. was founded in 2001 and is based in Lake Forest, California.

About Sight Sciences

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.